Modern vaccines are producing antibodies in the
Photo: Reuters
Experimental application of the modern coronavirus vaccine has also been shown in older people. The Massachusetts-based biotechnology company Moderna released the results of a small experiment on older people on Wednesday. They claim that the coronavirus vaccine has produced the same number of antibodies in 56-year-olds as it did in preliminary tests.
Forbes Online reported on Wednesday that people over the age of 50 are considered the most at risk for coronary heart disease. It was feared that the corona vaccine would not provide adequate protection for the elderly. But the modern vaccine has given them promising results.
According to the US Centers for Disease Control and Prevention, older people have a higher risk of hospitalization and death than younger people. This is because their immunity usually weakens with age. So it is difficult for any vaccine to be effective in their body.
Modern has tested the vaccine on 10 people aged 58 to 60 and 10 people aged 61 and over. It has been found that the same amount of antibodies is produced in the body of older people as in young people.
The results of the vaccine test by Moderner last July said that their vaccine showed an immune response in people between the ages of 18 and 55. The vaccine is safe and has no side effects. At that time, the organization said that the vaccine would be tested on the bodies of more elderly people.
Modern has tested the vaccine on 10 people aged 58 to 60 and 10 people aged 61 and over. It has been found that the same amount of antibodies are produced in the body of older people as in young people. Apart from this, no serious side effects were seen in it. It is tolerant. The information, published by Modern, however, was not published in any peer-reviewed journal. However, they have presented this information to the experts.
Earlier this month, US President Donald Trump announced the purchase of 100 million doses of the modern vaccine for 1.5 billion US dollars. The Modern Vaccine is part of Operation Rapid Speed, a U.S. rapid vaccination campaign. Through this program, the United States wants to get at least one effective vaccine before the end of this year. The United States will take its first shipment as soon as an effective vaccine is approved.
The United States has signed deals with a number of other companies, including Modern. These include Johnson & Johnson, Pfizer, NovaVax, AstraZeneca, GlaxoSmithKline and Sanofi. The Trump administration has already provided কোটি 955 million for modern vaccine research and development.
Forbes reports that any vaccine could prove safe and effective early next year. But Anthony Fawcett, the top infectious disease specialist in the United States, said he did not expect the vaccine to be available to everyone until 2021.
The third phase of the modern vaccine is being tested in the United States, according to AFP. Modern vaccines are based on messenger RNA (mRNA), which carries the genetic material of the virus and teaches the body's immune system to fight the virus. The announcement of possible advances in vaccine development in the United States came after seeing the positive results of the first phase of modern testing. In the first stage of modern testing, antibodies against the virus were found in the bodies of all 45 volunteers.
According to Forbes, Stephen Bansell, the CEO of Modern, has a net worth of ২১ 2.1 billion. Bansell rose to the top of the list of millionaires when the share price of Moderner rose last April. After the positive results of the first phase of the modern ticker announced their second phase test, their share price went up.
It's very critical article I also enjoyed it.